von Knoch Fabian, Eckhardt Christina, Alabre Claude I, Schneider Erich, Rubash Harry E, Shanbhag Arun S
Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Biomaterials. 2007 Aug;28(24):3549-59. doi: 10.1016/j.biomaterials.2007.04.024. Epub 2007 Apr 20.
The long-term durability of total joint replacements is critically dependent on adequate peri-implant bone stock, which can be compromised by wear debris-mediated osteolysis. This study investigated the effects of bisphosphonates on enhancing peri-implant bone in the presence of clinically relevant ultra-high molecular weight polyethylene (UHMWPE) wear debris. Fiber-mesh coated titanium-alloy plugs were implanted bilaterally in the femoral condyles of 36 New Zealand white rabbits. Implants in the left femora were covered with submicron UHMWPE particles during surgery. Rabbits were administered either no drug, subcutaneous alendronate weekly (1.0mg/kg/week) or a single dose of intravenous zoledronate (0.015mg/kg). A total of 6/12 rabbits in each group were sacrificed at 6 weeks and the remainder at 12 weeks postoperatively. Peri-implant bone stock was analyzed radiographically and histomorphometrically. Radiographically, both bisphosphonates significantly increased periprosthetic cortical thickness at 6 weeks (p<0.0001; alendronate: +18%; zoledronate: +11%) and at 12 weeks (p=0.001; alendronate: +17%; zoledronate:+19%). Histomorphometrically, alendronate and zoledronate raised peri-implant bone volume (BV/TV) up to 2-fold after 6 weeks without added wear debris and more than 3-fold when wear debris was present. Furthermore a 6-week bisphosphonate treatment increased osteoid thickness in the absence of wear debris (alendronate: +132%, p=0.007; zoledronate: +67%, p=0.51) and in the presence of wear debris (alendronate: +134%, p=0.023; zoledronate: +138%, p=0.016). In summary, alendronate and zoledronate treatment increased periprosthetic bone stock in a rabbit femoral model, particularly in the presence of UHMWPE wear debris. These new findings suggest that bisphosphonates may more than compensate for the well-documented negative effects of wear debris on peri-implant bone stock. The combined antiresorptive and osteoanabolic effects of bisphosphonates on periprosthetic bone stock may have an important role for critically improving the biological fixation and ultimate durability of total joint arthroplasty.
全关节置换的长期耐用性严重依赖于植入物周围充足的骨量,而磨损颗粒介导的骨溶解会损害骨量。本研究调查了在存在临床相关的超高分子量聚乙烯(UHMWPE)磨损颗粒的情况下,双膦酸盐对增强植入物周围骨量的影响。将纤维网涂层钛合金塞双侧植入36只新西兰白兔的股骨髁。手术过程中,左侧股骨的植入物覆盖有亚微米级UHMWPE颗粒。兔子分别接受无药物治疗、每周皮下注射阿仑膦酸钠(1.0mg/kg/周)或单次静脉注射唑来膦酸(0.015mg/kg)。每组12只兔子中,分别有6只在术后6周处死,其余在术后12周处死。通过影像学和组织形态计量学分析植入物周围的骨量。影像学结果显示,两种双膦酸盐在6周时(p<0.0001;阿仑膦酸钠:增加18%;唑来膦酸:增加11%)和12周时(p=0.001;阿仑膦酸钠:增加17%;唑来膦酸:增加19%)均显著增加假体周围皮质厚度。组织形态计量学结果显示,在无额外磨损颗粒的情况下,阿仑膦酸钠和唑来膦酸在6周后使植入物周围骨体积(BV/TV)增加高达2倍,在有磨损颗粒时增加超过3倍。此外,为期6周的双膦酸盐治疗在无磨损颗粒时(阿仑膦酸钠:增加132%,p=0.007;唑来膦酸:增加67%,p=0.51)和有磨损颗粒时(阿仑膦酸钠:增加134%,p=0.023;唑来膦酸:增加138%,p=0.016)均增加类骨质厚度。总之,在兔股骨模型中,阿仑膦酸钠和唑来膦酸治疗增加了假体周围骨量,尤其是在存在UHMWPE磨损颗粒的情况下。这些新发现表明,双膦酸盐可能足以弥补磨损颗粒对植入物周围骨量的不良影响。双膦酸盐对假体周围骨量的抗吸收和促骨合成联合作用可能对显著改善全关节置换术的生物固定和最终耐用性具有重要作用。